Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -128,896 | -56,891 | -39,527 | -241,598 | -149,421 |
| Depreciation Amortization | 161 | 97 | 52 | 113 | 62 |
| Accounts payable and accrued liabilities | -409 | 1,860 | 2,251 | -12,948 | -9,751 |
| Other Working Capital | -12,509 | -13,492 | 10,351 | -32,674 | -24,694 |
| Other Operating Activity | 34,745 | -5,713 | -9,595 | 128,543 | 62,721 |
| Operating Cash Flow | $-106,908 | $-74,139 | $-36,468 | $-158,564 | $-121,083 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -153,629 | -156,177 | -9,629 | -62,176 | N/A |
| PPE Investments | -146 | -104 | -16 | -672 | -669 |
| Other Investing Activity | 0 | 0 | 12,500 | 0 | 0 |
| Investing Cash Flow | $-153,775 | $-156,281 | $2,855 | $-62,848 | $-669 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 17,422 | 11,530 | 8,105 | 661,036 | 204,400 |
| Other Financing Activity | -1,586 | -1,586 | -1,586 | -1,529 | -1,504 |
| Financing Cash Flow | $15,836 | $9,944 | $6,519 | $659,507 | $202,896 |
| Exchange Rate Effect | 12,819 | 12,597 | 3,771 | -6,802 | 1,135 |
| Beginning Cash Position | 771,743 | 771,743 | 771,743 | 340,450 | 340,450 |
| End Cash Position | 539,715 | 563,864 | 748,420 | 771,743 | 422,729 |
| Net Cash Flow | $-232,028 | $-207,879 | $-23,323 | $431,293 | $82,279 |
| Free Cash Flow | |||||
| Operating Cash Flow | -106,908 | -74,139 | -36,468 | -158,564 | -121,083 |
| Capital Expenditure | -146 | -104 | -16 | -672 | -669 |
| Free Cash Flow | -107,054 | -74,243 | -36,484 | -159,236 | -121,752 |